#YomeishuSeizo

Yomeishu Seizo plans to apply its 101,000 shares of Hisamitsu Pharmaceutical Co., Inc. in Taiyo Kosan's tender offer at approximately 6,082 yen/share, totaling about 614 million yen. An extraordinary income of approximately 413 million yen is expected to be recorded in the fiscal year ending March 2026.

Regarding certain media reports about the privatization of the Company's shares and business sales, the Company denies that it is the source of the announcement and states that no decisions have been made on buyers or transaction terms at this time.

For the third quarter of the fiscal year ending March 2026, net sales were 7,327 million yen (5.2% decrease Year-over-Year), operating income was 128 million yen (28.5% increase Year-over-Year), and quarterly net income was 488 million yen (15.0% increase Year-over-Year).